Immuneering (IMRX) Accumulated Expenses (2020 - 2026)

Immuneering's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 9.58% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 9.58% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, up 57.69% from the prior year.
• Accumulated Expenses slipped to $3.1 million in Q1 2026 per IMRX's latest filing, from $7.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $7.8 million in Q4 2025 and bottomed at $1.7 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $3.4 million (2025), against an average of $3.9 million.
• Biggest YoY gain for Accumulated Expenses was 20095.41% in 2022; the steepest drop was 32.91% in 2022.
• Year by year, Accumulated Expenses stood at $4.5 million in 2022, then grew by 14.95% to $5.2 million in 2023, then dropped by 3.88% to $5.0 million in 2024, then jumped by 57.69% to $7.8 million in 2025, then slumped by 60.93% to $3.1 million in 2026.
• Per Business Quant, the three latest IMRX Accumulated Expenses figures stand at $3.1 million (Q1 2026), $7.8 million (Q4 2025), and $7.5 million (Q3 2025).